← Leaderboards
Yulia Nefedova
Wistar Institute
$9,218,395
Attributed
$12,887,237
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,887,237 · 8
By mechanism
R01$12,247,294 · 6
R21$467,835 · 1
F32$172,108 · 1
Top collaborators
- Valerian E Kagan7 shared
- Yuri Bunimovich3 shared
- Serge Y Fuchs3 shared
- Dan Toby Vogl2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsRegulationMalignant NeoplasmsSignal TransductionNeutrophilMediatingResponseTumor ProgressionMyeloid CellsTumor MicroenvironmentTumorMacrophageMyeloid-Derived Suppressor CellsImmuneNovel TherapeuticsBone MarrowMonocyteMyelogenousPlayCancer CellNeoplastic CellResistanceBasePathologic
Grant awards (29)
Therapeutic targeting MDSC-mediated immune suppression in cancer$696,515
R01 · FY2025 · CA · contact PI
Re-engineering differential regulation of ferroptosis in melanoma microenvironment$642,352
R01 · FY2025 · CA
Therapeutic targeting MDSC-mediated immune suppression in cancer$661,690
R01 · FY2024 · CA · contact PI
Re-engineering differential regulation of ferroptosis in melanoma microenvironment$642,352
R01 · FY2024 · CA
Re-engineering differential regulation of ferroptosis in melanoma microenvironment$690,908
R01 · FY2023 · CA
Therapeutic targeting MDSC-mediated immune suppression in cancer$682,585
R01 · FY2023 · CA · contact PI
Regulation of neonatal inflammation by myeloid-derived suppressor cells$634,964
R01 · FY2023 · HL · contact PI
Therapeutic targeting MDSC-mediated immune suppression in cancer$714,368
R01 · FY2022 · CA · contact PI
Regulation of neonatal inflammation by myeloid-derived suppressor cells$597,907
R01 · FY2022 · HL · contact PI
Negative regulation of myeloid-derived suppressive cells in cancer$461,819
R01 · FY2022 · CA · contact PI
Regulation of neonatal inflammation by myeloid-derived suppressor cells$631,459
R01 · FY2021 · HL · contact PI
Negative regulation of myeloid-derived suppressive cells in cancer$471,244
R01 · FY2021 · CA · contact PI
Regulation of neonatal inflammation by myeloid-derived suppressor cells$654,629
R01 · FY2020 · HL · contact PI
Negative regulation of myeloid-derived suppressive cells in cancer$547,478
R01 · FY2020 · CA · contact PI
Extracellular DNA in regulation of multiple myeloma$427,973
R01 · FY2020 · CA · contact PI
Extracellular DNA in regulation of multiple myeloma$415,133
R01 · FY2019 · CA · contact PI
Extracellular DNA in regulation of multiple myeloma$427,973
R01 · FY2018 · CA · contact PI
Extracellular DNA in regulation of multiple myeloma$427,973
R01 · FY2017 · CA · contact PI
Regulation of multiple myeloma by S100A9 protein$207,886
R21 · FY2017 · CA · contact PI
Extracellular DNA in regulation of multiple myeloma$450,473
R01 · FY2016 · CA · contact PI
Regulation of multiple myeloma by S100A9 protein$259,949
R21 · FY2016 · CA · contact PI
Notch as a New Therapeutic Target in Hematological Malignancies$291,582
R01 · FY2012 · CA · contact PI
Notch as a New Therapeutic Target in Hematological Malignancies$263,212
R01 · FY2011 · CA · contact PI
Notch as a New Therapeutic Target in Hematological Malignancies$271,353
R01 · FY2010 · CA · contact PI
Notch as a New Therapeutic Target in Hematological Malignancies$271,353
R01 · FY2009 · CA · contact PI
Notch as a New Therapeutic Target in Hematological Malignancies$269,999
R01 · FY2008 · CA · contact PI
Jak/STAT and dendritic cell differentiation in cancer$58,036
F32 · FY2006 · CA · contact PI
Jak/STAT and dendritic cell differentiation in cancer$57,536
F32 · FY2005 · CA
Jak/STAT and dendritic cell differentiation in cancer$56,536
F32 · FY2004 · CA